Timing Baseline Marker Comprehensive metabolic panel (CMP) Why it matters Reviews liver, kidney, electrolyte, and glucose context in one broad panel
Healthcare providers are monitoring this development with interest as additional trial data becomes available
Weight Loss Clinical Research Study Overweight
Precision is also paramount in terms of getting optimal treatment for people, and the appeal of different treatments might differ amongst people. GLP-1 Treatments Face Hurdles While GLP-1s offer promising benefits for some patients, significant barriers remain regarding supply, cost, and insurance coveragechallenges that Saunders describes as humongous limitations. Novo Nordisks Ozempic and Wegovy have been on the FDAs drug shortage list since 2022
Impact of Glucagon-Like Peptide-1 Receptor Agonists on Incident Dementia Risk. PMC Dementia Researcher/NiHR
In addition to glycaemic control, SGLT2 inhibitors offer a useful weight loss and a low risk of hypoglycaemia, and their ease of use and good tolerability has led to extensive use in primary care